Kura Oncology Statistics
Total Valuation
Kura Oncology has a market cap or net worth of $528.94 million. The enterprise value is -$173.78 million.
Important Dates
The next estimated earnings date is Thursday, May 1, 2025, after market close.
| Earnings Date | May 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Kura Oncology has 80.75 million shares outstanding. The number of shares has increased by 17.66% in one year.
| Current Share Class | 80.75M |
| Shares Outstanding | 80.75M |
| Shares Change (YoY) | +17.66% |
| Shares Change (QoQ) | +0.21% |
| Owned by Insiders (%) | 0.86% |
| Owned by Institutions (%) | 77.31% |
| Float | 59.77M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.27 |
| Forward PS | 7.31 |
| PB Ratio | 1.33 |
| P/TBV Ratio | 1.30 |
| P/FCF Ratio | 4.01 |
| P/OCF Ratio | 4.00 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.46, with a Debt / Equity ratio of 0.04.
| Current Ratio | 9.46 |
| Quick Ratio | 9.32 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.12 |
| Interest Coverage | -119.33 |
Financial Efficiency
Return on equity (ROE) is -42.91% and return on invested capital (ROIC) is -28.59%.
| Return on Equity (ROE) | -42.91% |
| Return on Assets (ROA) | -19.97% |
| Return on Invested Capital (ROIC) | -28.59% |
| Return on Capital Employed (ROCE) | -28.35% |
| Revenue Per Employee | $280,641 |
| Profits Per Employee | -$906,161 |
| Employee Count | 192 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Kura Oncology has paid $2.02 million in taxes.
| Income Tax | 2.02M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -69.43% in the last 52 weeks. The beta is 0.84, so Kura Oncology's price volatility has been lower than the market average.
| Beta (5Y) | 0.84 |
| 52-Week Price Change | -69.43% |
| 50-Day Moving Average | 7.79 |
| 200-Day Moving Average | 14.67 |
| Relative Strength Index (RSI) | 32.63 |
| Average Volume (20 Days) | 1,124,437 |
Short Selling Information
The latest short interest is 9.02 million, so 11.17% of the outstanding shares have been sold short.
| Short Interest | 9.02M |
| Short Previous Month | 9.21M |
| Short % of Shares Out | 11.17% |
| Short % of Float | 15.09% |
| Short Ratio (days to cover) | 7.52 |
Income Statement
In the last 12 months, Kura Oncology had revenue of $53.88 million and -$173.98 million in losses. Loss per share was -$2.02.
| Revenue | 53.88M |
| Gross Profit | -101.46M |
| Operating Income | -193.20M |
| Pretax Income | -181.75M |
| Net Income | -173.98M |
| EBITDA | -192.35M |
| EBIT | -193.20M |
| Loss Per Share | -$2.02 |
Full Income StatementBalance Sheet
The company has $727.40 million in cash and $16.59 million in debt, giving a net cash position of $710.80 million or $8.80 per share.
| Cash & Cash Equivalents | 727.40M |
| Total Debt | 16.59M |
| Net Cash | 710.80M |
| Net Cash Per Share | $8.80 |
| Equity (Book Value) | 413.64M |
| Book Value Per Share | 5.29 |
| Working Capital | 666.12M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $134.32 million and capital expenditures -$472,000, giving a free cash flow of $133.85 million.
| Operating Cash Flow | 134.32M |
| Capital Expenditures | -472,000 |
| Free Cash Flow | 133.85M |
| FCF Per Share | $1.66 |
Full Cash Flow StatementMargins
| Gross Margin | -188.30% |
| Operating Margin | -358.55% |
| Pretax Margin | -319.15% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | 248.40% |
Dividends & Yields
Kura Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.66% |
| Shareholder Yield | -17.66% |
| Earnings Yield | -32.40% |
| FCF Yield | 24.92% |
Analyst Forecast
The average price target for Kura Oncology is $25.50, which is 289.31% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $25.50 |
| Price Target Difference | 289.31% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 69.85% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Kura Oncology has an Altman Z-Score of 1.1 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.1 |
| Piotroski F-Score | 3 |